Latest news with #DiMe
Yahoo
15-05-2025
- Health
- Yahoo
New DiMe Seal Sets Benchmarks for Digital Health Products
Digital Medicine Society (DiMe) and Elevance Health collaborate to evaluate and elevate digital health software products BOSTON, May 15, 2025 /PRNewswire/ -- The Digital Medicine Society (DiMe) and Elevance Health have teamed up to simplify identifying trustworthy digital health products. The "DiMe Seal" (launched last year) is awarded to digital health software products (DHSPs) based on an assessment of usability, privacy and security, and evidence. This collaboration allows us to further assess DHSPs with a clinical component. Elevance Health will provide a clinical evidence assessment. DiMe will award its distinguished "DiMe Seal" to DHSPs that meet all its evaluation requirements. Each benchmark reflects a core value that users, healthcare providers, and payers expect from a trusted product. Annual reviews will ensure ongoing compliance with the latest industry standards and guidelines. With over 350,000 health apps available, including more than 30,000 for clinicians and healthcare administrators, it is increasingly difficult to identify high-quality, trustworthy options. A consumer-focused approach is needed to drive robust adoption of healthcare technologies. The DiMe Seal addresses this challenge by recognizing DHSPs that meet rigorous standards and are most likely to improve health outcomes. Elevance Health's clinical evidence assessment is anchored in the Evidence DEFINED framework, created through a collaboration led by DiMe in 2023, to help payers and other organizations quickly determine the clinical value of digital health products. "To improve health outcomes at scale, it is critical for the digital health industry to move in an evidence-based direction. Elevance Health is proud to lead in the clinical evaluation of digital health software products," said Jordan Silberman, MD, PhD, Director of Clinical Analytics & Research, Elevance Health. "Strategic partnerships and responsible innovation are essential for fostering trust in these products among individuals and their care teams." "Clinical evidence assessment is often lengthy and costly. By embedding this critical component into the DiMe Seal process, we help developers address clinical needs and validate their products' value," said Doug Mirsky, Vice President, Digital Medicine Society. "With Elevance Health's rigorous clinical assessment, it becomes simpler for health systems, clinicians, and users to adopt effective new technologies." To start the process to obtain a DiMe Seal, or to learn more, click here. About the Digital Medicine Society: DiMe is a global non-profit and the professional home for all members of the digital medicine community. Together, we tackle the toughest digital medicine challenges, develop clinical-quality resources on a technology timeline, and deliver these actionable resources to the field via open-source channels and educational programs. Media Contact: Carla English, press@ View original content to download multimedia: SOURCE Digital Medicine Society (DiMe) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
13-02-2025
- Health
- Associated Press
DATAcc by DiMe Releases New Resources to Support the Development of Digital Health Technologies to Predict and Manage Cancer Immunotherapy Side Effects
New resources will support developers and researchers in developing de-risking digital products to better predict and manage Cytokine Release Syndrome BOSTON, Feb. 13, 2025 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe), the global home for digital health measures development, released new resources to support the development of digital health technologies (DHTs) for predicting and managing Cytokine Release Syndrome (CRS), a serious side effect of cancer immunotherapies. Over the past few decades, immunotherapies have shown significant promise in treating hematological cancers like leukemia, lymphoma, and multiple myeloma, offering hope to patients with limited treatment options. However, these therapies also bring the risk of CRS, a potentially fatal condition that presents as flu-like symptoms but can quickly escalate to life-threatening complications if not properly managed. The risk of CRS often requires therapies to be administered in a hospital setting or frequent clinical visits, increasing clinical trial costs, especially for patients in underserved or rural areas, and burden on healthcare systems. The lack of standard reporting and a robust, high-frequency collection of clinical measures related to CRS presents barriers to developing high-quality CRS de-risking products. DATAcc's new resources advance the development of CRS de-risking products that may improve care delivery, reduce hospital dependency, and expand immunotherapies for all patients. 'Immunotherapies are lifesaving, but dangerous side effects like CRS create barriers for too many,' said Samantha McClenahan, DiMe. 'The resources launched today will support developers in building the products needed for de-risking CRS outside clinical settings. Leveraging DHTs can help reduce the risk of CRS and get these therapies to patients in need. We're excited to launch resources that will fast-track the development of these new digital products.' 'Immunotherapies are a critical, innovative intervention in the fight against cancer, but today they can be costly and prohibitive for many patients due to the need to monitor for dangerous side effects,' said Cindy Varga, Atrium Health. 'Using CRS de-risking tools during treatment, we could more quickly detect CRS symptoms and intervene earlier to mitigate high grade complications during a cancer patient's treatment journey. Expanding the availability of CRS de-risking tools will help oncologists and researchers detect and manage CRS more effectively, enabling patients to spend less time in inpatient settings and reducing the burden on healthcare systems, patients, and caregivers.' DATAcc is the leader in advancing the use of digital clinical measures by stakeholders across our industry. The new resources launched today accompany existing digital measures resources in physical activity, Alzheimer's disease and related disorders, nocturnal scratch, and sleep. We are tackling some of the biggest challenges and opportunities in the digital medicine ecosystem. To change the digital health landscape as a DiMe or DATAcc partner, click here. About the Digital Medicine Society: DiMe is a global non-profit and the professional home for all members of the digital medicine community. Together, we tackle the toughest digital medicine challenges, develop clinical-quality resources on a technology timeline, and deliver these actionable resources to the field via open-source channels and educational programs. About DATAcc by DiMe: The Digital Health Measurement Collaborative Community ( DATAcc) by DiMe is a collaborative community with the FDA's Center for Devices and Radiological Health. We provide a forum for collaboration where partners and experts from across the digital health field work to advance the use of digital health measures in research to improve lives.
